Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 4/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | CALCR | P30988 | 2/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050544 | 0.94 | CTSL (0.53) | MC4RCTSLCTSSCTSKCTSH | |
| SCHEMBL7200318 | 0.89 | CTSL (0.49) | MC4RCTSLCTSSCTSKCTSH | |
| SCHEMBL7200319 | 0.89 | CTSL (0.49) | MC4RCTSLCTSSCTSKCTSH | |
| SCHEMBL30910841 | 0.83 | CTSL (0.52) | MC4RCTSLCTSSCTSKCTSH | |
| SCHEMBL30366772 | 0.82 | MC4R (0.47) | MC4ROPRM1OPRD1F2BDKRB2 | |
| SCHEMBL30567437 | 0.82 | OPRM1 (0.56) | CTSLCTSSCTSKCTSHOPRM1 | |
| SCHEMBL30456911 | 0.82 | APLNR (0.52) | CTSLCTSSCTSKCTSHOPRM1 | |
| SCHEMBL29972919 | 0.81 | F2 (0.55) | MC4RCTSLCTSSCTSKCTSH | |
| SCHEMBL31505801 | 0.81 | CTSL (0.56) | MC4RCTSLCTSSCTSKCTSH | |
| SCHEMBL30969039 | 0.81 | APLNR (0.55) | CTSLCTSSCTSKCTSHF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269226-A1 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | HALLSTAT CAPITAL, LLC | 2024-08-15 | — | — | US | claimed |
| US-20240269226-A1 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | HALLSTAT CAPITAL, LLC | 2024-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269226-A1 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | CNR2, CNR1, BAD | MC4R 490/4885CTSL 2347/4885CTSS 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.